Portfolio
To address AMR and protect the lives of people around the world, PACE is providing funding and support for a portfolio of early-stage projects to help grow the pipeline of high-quality antimicrobial therapeutics and associated diagnostics.
Supporting the best innovations to address the global threat of AMR
We are supporting a diverse portfolio of projects aimed at developing new tests and treatments for bacterial infections with high unmet need. Through a series of funding rounds available to academics and SMEs worldwide, we are selecting, investing in and supporting the most promising projects. We are offering a collaborative approach to project development through access to advisors, mentors, potential project partners and enabling technologies and capabilities. By supporting the projects in this way, we are helping to give them the best chance of success and position them for onward funding, investment and development. More projects will enter the portfolio as the programme progresses. This page highlights the innovators and projects that are currently in the PACE portfolio.
Number of projects supported
PACE funds committed to projects
Number of organisations funded
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
Glox Therapeutics
Glox Therapeutics are developing precision antibiotics to combat antimicrobial resistance. Our goal is to create potent, species-specific antibiotics that, unlike conventional antibiotics, do not harm the host microbiome. We are producing engineered bacteriocins from our proprietary platform technologies to target Gram-negative pathogens.
